Forest strives to positively impact the health and quality of life of patients through the development of innovative prescription drug therapies.
11.02.2009 - Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation
10.28.2009 - Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
10.20.2009 - Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per Share of $0.61, Including a Net $0.24 Per Share Charge for One-Time Items